

RESEARCH

Open Access

Characterization of an Ebosin derivative produced by heterologous gene replacement in *Streptomyces* sp. 139

Yang Zhang^{1†}, Junjie Shan^{2†}, Yonggang Bao^{1†}, Liping Bai¹, Rong Jiang¹, Lianhong Guo¹, Chen Yao¹, Ren Zhang³ and Yuan Li^{1*}

Abstract

Background: Ebosin is a novel exopolysaccharide (EPS) produced by *Streptomyces* sp. 139 and evidenced to possess an anti-rheumatic arthritis activity *in vivo*. The Ebosin biosynthesis gene cluster (*ste*) consists of 27 ORFs and *ste7* has previously been demonstrated to code for a fucosyltransferase, which plays an essential role in the formation of repeating sugar units during Ebosin production. Aiming to generate derivatives of Ebosin for better activity, we replaced *ste7* with a gene encoding for a glucosyltransferase (*gtf*) from *Streptococcus thermophilus*.

Results: This alteration resulted in a novel Ebosin derivative (EPS-7 g) with its monosaccharide composition dramatically changed, especially in the proportion of glucose which increased from 1.1% (Ebosin) to 84.01% (EPS-7 g). In an ELISA analysis, EPS-7 g exhibited a higher binding activity for IL-1R, as a competitor of interleukin-1, than that of Ebosin. It also exhibited a higher inhibitory effect on the activity of IL-1 β -converting enzyme and production of IL-1 β in fibroblast-like synoviocytes (FLS). In addition, experiments with acute inflamed mice induced by croton oil showed a significantly higher anti-inflammatory activity of EPS-7 g compared with Ebosin.

Conclusions: The new Ebosin derivative EPS-7 g is more bioactive than Ebosin evaluated by a series of experiments. This is the first report demonstrating a modification of EPS structure via heterologous gene replacement in *Streptomyces*.

Keywords: Ebosin derivative, Heterologous gene replacement, Gene *gtf*, Gene *ste7*, *Streptomyces*, *Streptococcus thermophilus*

Background

One type of microbial polysaccharides are secreted out of the cells [1] and therefore called exopolysaccharides (EPSs), which are long-chain polysaccharides consisting of branched, repeating units of sugars or sugar derivatives [2]. In bacteria, EPS biosynthesis starts with the intracellular formation of EPS precursors and the sugar nucleotides, followed by the formation of a repeating unit on a lipid carrier which is located in the cytoplasmic membrane. The later steps involve transport of the repeating units across the membrane to the outer layer

and polymerization of tens and even hundreds of such units to form the final EPSs [3]. During the process, glycosyltransferases play important roles to sequentially transfer sugars from intracellular nucleotide sugars to a lipid carrier acceptor [4].

In order to improve applications of EPSs, genetic engineering can be used in the production of desired polysaccharides targeting predefined macroscopic properties.

Based on the available genetic information, genetic modification of *eps* genes should lead to EPSs with a different repeating unit or with a different chain length [5]. Manipulation of genes which function in export, polymerization, and determination of chain length during EPS biosynthesis were also proved effective for altering EPS structure [6]. Heterologous production of an EPS has been successful by transfer of the complete *eps* gene cluster alone of a LAB strain into a non EPS-producing

* Correspondence: yuanwli@263.net

†Equal contributors

¹Key laboratory of Biotechnology of Antibiotics, Ministry of Health, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tian Tan, 100050 Beijing, China

Full list of author information is available at the end of the article

heterologous host, provided that the heterologous host possessed all necessary genetic information for precursor synthesis [7]. Ingeborg et al [8] described increased exopolysaccharide production in *Lactococcus lactis* due to manipulated overexpression of the NIZO B40 *eps* gene cluster, the first report demonstrating that homologous overexpression of a complete *eps* gene cluster in *Lactococcus lactis* leads to increased EPS production.

Streptomyces are a group of gram-positive bacteria that have been intensively studied for their secondary metabolites, particularly antibiotics. However, little is known of the production of EPSs in *Streptomyces*. Recently a novel EPS namely Ebosin was isolated from the supernatants of fermentation cultures of *Streptomyces* sp. 139 [9], which has remarkable anti-rheumatic arthritis activity *in vivo* [10]. Its biosynthesis gene cluster (*ste*) consisting of 27 ORFs was also identified [11]. Efforts have been made in elucidating the function of individual *ste* genes [12-15]. Insights into the biosynthesis pathways of polysaccharides are crucial for the exploitation of microorganisms to produce polysaccharides of industrial or medicinal importance. With a number of the *ste* genes identified, it is now possible to carry out specific manipulations for creating Ebosin derivatives which can then be screened for better bioactivities. This paper reports our endeavor to generate such derivatives by tackling the *ste7* gene encoding a fucosyltransferase, which catalyzes the transfer of fucose specifically from GDP-fucose to a fucose acceptor during Ebosin biosynthesis [16]. In this study, we replaced *ste7* with the glucosyltransferase gene (*gtf*) from *Streptococcus thermophilus*, which is a gram-positive bacterium and most valuably used in food industry. Stingle et al [17] identified the *eps* genetic locus of *S. thermophilus* Sfi6, revealing a 15.25-kb region containing 16 open reading frames (ORFs), within a 14.52-kb region encodes 13 genes (*epsA* to *epsM*) capable of directing EPS synthesis. The resultant EPS-7 g produced by the strain *Streptomyces* sp. 139 (*gtf*) has a very high content of glucose and exhibited remarkably higher bioactivities than that of Ebosin in both *in vitro* and *in vivo* assays.

Results

Construction of the heterologous gene replacement strain *Streptomyces* sp. 139 (*gtf*)

The replacement of *ste7* gene by the *gtf* gene of *S. thermophilus* (Figure 1A) was evidenced by Southern hybridization using a 1.03-kb DNA (F1) as probe upstream of *ste7* (Figure 1B). The hybridization signals appeared with the expected sizes of 4.0 kb for *Streptomyces* sp. 139 (*gtf*) and 3.1 kb for *Streptomyces* sp. 139 (*ste7*). This result indicated that the colonies with thio^r Am^s phenotypes had integrated the *gtf-thio^r* cassette into the kanamycin resistance gene, therefore, confirmed the establishment of heterologous gene replacement strain *Streptomyces* sp. 139 (*gtf*).

Sugar composition of EPSs

GC analysis of Ebosin, EPS-7 m produced by the knock mutant *Streptomyces* sp. 139 (*ste7*) and EPS-7 g by *Streptomyces* sp. 139 (*gtf*) (Figure 2A, B, C) showed that these EPSs consisted of the same monosaccharides: glucose, mannose, arabinose, galactose, fucose, xylose and rhamnose, of which the most striking was an increase of glucose proportion from 1.1% (Ebosin) to 84.01% (EPS-7 g). While, some proportional changes of other sugars also occurred in comparison with Ebosin (Figure 2D). Using a method based on uronic acid carbazole reaction, galacturonic acid was also found in EPS-7 m and EPS-7 g.

The competitive binding activity of Ebosin derivatives with IL-1 for IL-1R

Using an ELISA assay, the competitive binding activities of Ebosin, EPS-7 m and EPS-7 g with IL-1 for IL-1R were determined.

For EPS-7 m they were 6.1% and nil ($P < 0.05$) at dosages of 0.64 ng/ μ L and 0.128 ng/ μ L respectively, which were remarkably lower than those of Ebosin (24.2%, 13.7%) at the same dosages. Higher binding activities of EPS-7 g were detected to be 27.1% and 24.3% ($P < 0.05$) respectively compared with that of Ebosin at same concentrations (Figure 3).

Effect of Ebosin derivatives on the enzymatic activity for IL-1 β -converting enzyme (ICE)

At concentrations of 0.64 ng/ μ L and 0.128 ng/ μ L, Ebosin suppressed the enzyme with inhibition ratios 35.5% and 25.0% respectively, compared with 15.5% ($P < 0.05$), 14.3% for EPS-7 m and 47.6%, 35.7% ($P < 0.05$) for EPS-7 g respectively (Figure 4A). The results demonstrated a higher activity of EPS-7 g to inhibit the IL-1 β -converting enzyme.

Inhibiting effect of Ebosin derivatives on production of IL-1 β in FLS cells

To assess the effects of Ebosin, EPS-7 m and EPS-7 g on production of IL-1 β in FLS (fibroblast-like synoviocytes), cell cultures were carried out and stimulated with LPS at 37°C for 72 h before analyzed by ELISA. The results indicated (Figure 4B) that Ebosin, EPS-7 m and EPS-7 g at dosage of 3.2 ng/ μ L reduced the IL-1 β production 52.03% ($P < 0.01$), 26.17%, 58.70% ($P < 0.01$) respectively and 45.57% ($P < 0.5$), 15.39%, 52.34% ($P < 0.01$) at dosage of 0.64 ng/ μ L separately. With dosage of 0.128 ng/ μ L, the IL-1 β production were suppressed 31.61%, 10.16% and 47.82% ($P < 0.01$) individually.

Effect of Ebosin and EPS-7 g on the inflammatory activity in the acute inflamed mice induced by croton oil

To evaluate the effect of Ebosin and EPS-7 g on the acute inflamed mice induced by croton oil, the mice were randomly divided into three groups described as above. Ebosin




Figure 1 The diagram of gene replacement and Southern blot analysis. **(A)** Diagram of gene replacement of *ste7* with *gtf* originated from *Streptococcus thermophilus* through a double crossover via homologous recombination. Gray box indicates the location of Km^r gene in *Streptomyces* sp. 139 (*ste7*). Restriction maps of *Streptomyces* sp. 139 (*ste7*) and the gene replacement strain *Streptomyces* sp. 139 (*gtf*) show the predicted fragment sizes upon *Bam*HI digestion. **(B)** Southern blot autoradiograph of *Streptomyces* sp. 139 (*ste7*) and *Streptomyces* sp. 139 (*gtf*). 1. Chromosome DNA of *Streptomyces* sp. 139 (*ste7*) digested with *Bam*HI; 2. chromosome DNA of *Streptomyces* sp. 139 (*gtf*) digested with *Bam*HI.

and EPS-7 g (100 mg/kg) were orally administered to each mouse of the respective experimental groups for 1 h before induction by croton oil. Compared with the acute inflamed mice groups untreated (control), the inhibition ratios of EPS-7 g and Ebosin for mice ear edema were 48.61% ($P < 0.05$) and 21.60% respectively (Figure 5), indicating that EPS-7 g surpasses Ebosin by over 100% on

suppressing the inflammatory activity in the acute inflamed mice.

Discussion

Exopolysaccharides include a range of diverse polymers that play vital roles in variety of biological processes. In addition, EPSs have also significant industrial applications,







Figure 2 GC chromatograms of sugar analysis of Ebosin (A), EPS-7 m (B) and EPS-7 g (C). 1. rhamnose, 2. fucose, 3. arabinose, 4. xylose, 5. mannose, 6. glucose, 7. galactose. (D). Monosaccharide compositions of Ebosin, EPS-7 m and EPS-7 g. Galacturonic acid was analyzed using a method based on uronic acid carbazole reaction (Bitter et al., 1962).



including their use as biothickeners in foods [4]. Notably, EPSs produced by lactic acid bacteria contribute significantly to the structure and viscosity of fermented milk products [18]. The health value of these macromolecules has also emerged in recent years; many reports indicate that they can confer health benefits on consumers arising from their immunogenic and cholesterol-lowering properties [19,20]. EPSs produced by *Trichoderma erinaceum* DG-312 was shown to have a strong anti-inflammatory activity in inflamed mice [21]. *Enterobacter cloacae* was also found to produce EPSs with anti-diabetic activity [22].



Metabolic engineering has enabled generation of “designer” polysaccharides in lactic acid bacteria (LAB), which mostly involved manipulations of glycosyltransferases [2]. Introducing new or existing glycosyltransferases into LAB [4] or gene shuffling with glycosyltransferases are effective means for controlling EPS structure [5]. Masja et al [23] reported that heterologous production of the pneumococcal serotype 14 polysaccharide in *Lactococcus lactis* resulted in the recombinant product secreted into culture medium, which simplified downstream processing. This was achieved by coexpressing the pneumococcal gene cluster *cpsFGHIJKL*₁₄ with the lactococcal regulatory and priming glycosyltransferase-encoding genes (*epsABCD*_{B40}) specific for B40 polysaccharide. Knoshaug et al [24] reported evidence for a novel gene organization expressing EPS in *Lactococcus lactis* subsp. *cremoris* Ropy352 and showed the specificities of polymerization and export enzymes blocking the function of just one glycosyltransferase abolished the production of ropy EPS. Heterologous expression of glycosyltransferases has been found to result in different sugars added at strategic positions in generating EPSs with new properties [5].

Ebosin is a novel EPS with anti-rheumatic arthritis activity. It has been shown that Ebosin is an inhibitor of IL-1β-converting enzyme (ICE), a key enzyme in synthesis of IL-1β [25]. More recently, evidence has also been obtained demonstrating that the anti-inflammatory effect of Ebosin on rat collagen-induced arthritis is through suppressing production of interleukin-1β, interleukin-6 and tumor necrosis factor α at both transcriptional and post-translational levels [10]. This EPS is therefore of medicinal value so improvement for better property is warranted. In this study, a glycosyltransferase *gtf* gene from *S. thermophilus* was expressed in replacement of the *ste7* gene which encodes a fucosyltransferase in the Ebosin-producing strain *Streptomyces* sp. 139. This brought about dramatic changes in the property of EPS produced. Because of the complexity of the biosynthesis pathway of Ebosin and involvement of a large number of genes, once *ste7* was replaced with the

heterologous gene *gtf*, dramatic effect was seen not only on the increased incorporation of glucose, but also on the overall sugar profile. The reason for these changes, which are apparently not a simple proportional change of composition with increased glucose, may lie in the primary structure. The resultant EPS-7 g turns out to be more bioactive compared with Ebosin evaluated by its ICE inhibitory activity, suppression of interleukin-1 β production in fibroblast-like synoviocytes (FLS), competitive binding to IL-1R against IL-1 and suppression of the acute inflammatory activity in the acute inflamed mice induced by croton oil. According to these results, it looks like that increasing proportion of glucose effects on bioactivity of EPS-7 g. A good understanding of the correlation between structure and bioactivity of Ebosin is important because it will provide a foundation for a strategy aimed at producing functionally more valuable polysaccharides. Continuing efforts in the elucidation of Ebosin biosynthesis pathway will enable more rational designs for genetic manipulation to generate highly effective derivatives.

Conclusions

EPS-7 g, a novel Ebosin derivate, was produced by heterologous gene replacement in *Streptomyces* sp. 139, which was more bioactive compared with Ebosin evaluated by a series of experiments. To our knowledge, this is the first report on manipulation of EPS structure by introducing heterologous glucosyltransferases into *Streptomyces*.

Methods

Bacterial strains and culture conditions

Streptomyces sp. 139 was isolated from a soil sample in China and kept in the China General Microbiology Culture Collection Center (No. 0405) (Table 1). *Streptomyces* sp.

139 (*ste7*) was generated previously [16] and kept in our laboratory. These strains were cultured at 28°C with shaking (250 rpm) in either TSB medium supplemented with 5 mM MgCl₂ and 0.5% glycine or fermentation medium (1% glucose, 2% starch, 2% soybean extract, 0.2% tryptone, 0.2% beef extract, 0.4% yeast extract, 0.05% K₂HPO₄, 0.3% CaCO₃, pH 7.3). *Streptococcus thermophilus* was obtained from China Industrial Microbiology Culture Collection Center (CICC 20370) (Table 1) and cultured in LB medium at 40°C.

Animal

Kunmin mice (male, 18-20 g, Certificate No. SCXK 2005-0013) and Wistar rats (male, 180 \pm 20 g, Certificate No.: SCXK 2005-0013) were purchased from the Institute of Experimental Animals, Chinese Academy of Medical Sciences, Beijing. All rats were housed under standard laboratory conditions with the approval of the Institute of Experimental Animals and Use Committee of Chinese Academy of Medical Sciences.

Cell culture of FLS (fibroblast-like synoviocytes)

Synovial tissues obtained from the knee joints of sacrificed CIA (collagen-induced arthritis) rats [26] on day 30 after immunization were minced and digested with type II collagenase (0.4%, Gibco) at 37°C in a humidified 5% CO₂ incubator for 2 h in Dulbecco's modified Eagle's medium (DMEM), thoroughly washed and then cultured in DMEM supplemented with fetal bovine serum (15%, Gibco). At confluence, adherent cells were trypsinized (0.25%, Hyclone) at 37°C for 0.5 h, filtered and extensively washed again. The adherent cells were cultured in DMEM containing fetal bovine serum, 100 units/mL penicillin and 100 μ g/mL streptomycin in a humidified

Table 1 Bacterial strains and plasmids used in this study

| Strain or plasmid | Description | Reference |
|--|--|------------|
| Strains | | |
| <i>E.coli</i> DH5 α | supE44 Δ lacU169 (ϕ 80 lacZ Δ M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 | [27] |
| <i>E. coli</i> DH5 α (pUC- <i>gtf</i>) | <i>E. coli</i> DH5 α clone with <i>gtf</i> | This study |
| <i>E. coli</i> ET12567 | Methylation-deficient <i>E. coli</i> dam ⁻ dcm ⁻ hsdM | [29] |
| <i>Streptomyces</i> sp. 139 | Ebosin producing strain | Lab stock |
| <i>Streptomyces</i> sp. 139 (<i>ste7</i>) | The gene <i>ste7</i> disruption mutant | This study |
| <i>Streptomyces</i> sp. 139 (<i>gtf</i>) | Am ^s , thio ^f , the heterologous gene replacement strain of <i>Streptomyces</i> sp.139 | This study |
| <i>Streptococcus thermophilus</i> | Wild type | CICC 20370 |
| Plasmids | | |
| pUC18 | Amp ^r , <i>E.coli</i> general cloning vector with multiple cloning site | [27] |
| pUC- <i>gtf</i> | Amp ^r , pUC18 derived plasmid carrying <i>gtf</i> gene | This study |
| pKC7 | Km ^r , Am ^r , pKC1139 derived plasmid carrying F1, F2 | This study |
| pKC7- <i>gtf</i> | pKC7 carrying <i>gtf</i> gene | This study |
| pEGM-T- <i>tsr</i> | pEGM-T carrying <i>thio^f</i> gene | Lab stock |

atmosphere of 5% CO₂ incubator for 24 h. FLS from passage 3-4 were seeded at 1 × 10⁶/mL in 24-well plates (Nunc) or at 1 × 10⁵/mL in 6-well plates in DMEM and cultivated at 37°C for 24 h.

DNA isolation and southern blot analysis

Isolation of *E. coli* plasmid DNA, *S. thermophilus* genomic DNA and standard recombinant DNA techniques were performed as described by Sambrook and Russell [27]. *Streptomyces* plasmid and genomic DNA was isolated as mentioned by Kieser et al [28]. For Southern blot analysis, the DIG high prime DNA labeling and detection starter kit II obtained from Roche (USA) was used following the instructions of manufacturer.

Cloning of the gene *gtf* of *Streptococcus thermophilus*

The genomic DNA isolated from 48-hour cultured *S. thermophilus* was used as template. The *gtf* gene was amplified by PCR using primers P1 and P2 (Table 2) in the following conditions: an initial denaturation at 94°C for 10 min; 30 cycles of 1 min at 94°C, 1 min at 47°C and 3 min at 72°C; and finally 10 min at 72°C. The amplified DNA fragment was cloned into plasmid pUC18 digested with *EcoRI* and *SalI* to construct pUC-*gtf*. The correct nucleotide sequence of *gtf* gene fragment cloned in pUC-*gtf* was verified by sequencing using an ABI PRISM 377XL DNA Sequencer (Applied Biosystems). Then the recombinant plasmid pUC-*gtf* was transformed into the strain *E. coli* DH5α to produce the strain *E. coli* DH5α (pUC-*gtf*). This plasmid pUC-*gtf* was isolated according the protocol mentioned by Sambrook and Russell [27].

Construction of the strain *Streptomyces* sp. 139 (*gtf*)

With the plasmid pEGM-T-ts_r (unpublished data) as template, the thiostrepton resistant gene (*thio^r*) was amplified by PCR using primers P3 and P4 (Table 2) in the following conditions: an initial denaturation at 94°C for 5 min; 30 cycles of 1 min at 94°C, 0.5 min at 58°C and 2 min at 72°C; and finally 10 min at 72°C. The amplified 1.06 kb gene fragment (*thio^r*) was inserted into plasmid pUC-*gtf* digested with *SalI*-*HindIII*, which was then digested by *XbaI* to isolate the fragment of *thio^r*-*gtf*. During construction of the *ste7* gene disrupted strain *Streptomyces* sp. 139 (*ste7*) in previous study [16], the gene *ste7* disruption vector pKC7 containing a 1.03-kb F1

fragment upstream of the gene *ste7* and a F2 0.899-kb fragment downstream of the gene *ste7* was created. The fragment of *thio^r*-*gtf* was introduced into the *ste7* disruption vector pKC7 at *XbaI* site to construct the gene replacement plasmid pKC7-*gtf*. Propagated in the methylation-deficient *E. coli* 12567 [29], pKC7-*gtf* was isolated and introduced into *Streptomyces* sp. 139 (*ste7*) by polyethylene glycol (PEG)-mediated protoplast transformation [28]. Incubated at 28°C for 16 to 20 h, the plates were overlaid with soft R2YE (0.7% agar) containing apramycin (40 μg/mL). Plasmid pKC7-*gtf* bears a temperature-sensitive *Streptomyces* replication origin [20] that is unable to replicate at temperatures above 34°C. Therefore, the transformants were first incubated at 28°C for 2 days until pinpoint size colonies became visible and then shifted to 37°C for further incubation. Strains resulted from a double crossover via homologous recombination grew out of the original pinpoint-size colonies in several days. The heterologous gene replacement strain *Streptomyces* sp. 139 (*gtf*) was selected by both apramycin sensitivity (Am^s, 40 μg/mL) and thiostrepton resistance (*thio^r*, 50 μg/mL).

Five *thio^r* Am^s colonies were selected randomly and the isolated genomic DNA originated from *Streptomyces* sp. 139 (*gtf*) and *Streptomyces* sp. 139 (*ste7*) [16] were digested with *BamHI* individually before DNA blot analysis.

Isolation of EPSs

The strains of *Streptomyces* sp. 139, *Streptomyces* sp. 139 (*ste7*) and *Streptomyces* sp. 139 (*gtf*) were cultured at 28°C for 96 h respectively. Following the protocol as described before [9], Ebosin, EPS-7 m and EPS-7 g were isolated from the supernatants of fermentation cultures of respective strains.

Monosaccharide analysis of EPSs

Sugar composition analysis was performed as described by Sun et al [30]. The purified polysaccharide samples (10 mg) was dissolved in 3 ml of 2 M TFA to hydrolyze at 115°C for 3 h, then drying under a stream of nitrogen. Subsequently, the residue was treated with 200 μL of 0.5 M Na₂CO₃ at 30°C for 45 min and added 1.5 mL of 4% NaBH₄ at room temperature for 2 h. After that, the sample was neutralized with 25% acetic acid and loaded onto a cation exchange resin column eluted with H₂O, then discharged the excess NaBH₄ with methanol. The sample residue was dried with P₂O₅ in vacuum at 85°C for 2 h and acetylated with 2.5 mL of acetic anhydride in 0.5 mL of pyridine at 100°C for 30 min. After cooling, the excess reagent was discharged under a stream of nitrogen and the sample was analyzed by Gas Chromatography (GC, HP5890, HEWLETT, Houston, TX, USA). Galacturonic acid was analyzed using a method based on uronic acid carbazole reaction [31].

Table 2 Oligonucleotide primers used in this study

| Primer | Sequence 5' - 3' |
|--------|--|
| P1 | 5'-GCGAATTC TCTAGAATGGCGTGGCTAATTAATG-3' |
| P2 | 5'-GCGTCGAGTTAATCGCTTTCAATA-3' |
| P3 | 5'-GCGTCGACAGGCGAATACTTCATATG-3' |
| P4 | 5'-GCAAGCTT TCTAGATGATCATCACTGACGAAT-3' |

Assay for IL-1R binding activity

The enzyme-linked immune specific assay (ELISA) method reported previously was used to analyze the binding activity for IL-1R of isolated EPSs [15].

Assay of the enzymatic activity for IL-1 β -converting enzyme (ICE)

We found recently that Ebosin is an inhibitor of IL-1 β -converting enzyme [32], a key enzyme in synthesis of IL-1 β . To assess the inhibitory effects of EPS-7 m [16] and EPS-7 g on ICE enzymatic activity, the assay was conducted according to the protocol reported by koizumi et al [33]. The enzymatic reactions were performed in 100 μ L reaction solution consisting of 20 mM HEPES (pH 7.5), 0.1 mM NaCl, 5 mM dithiothreitol, 10% sucrose, 250 μ M substrate N-acetyl-Tyr-Val-Ala-Asp- *p*-nitroanilide, 2.0 IU of IL-1 β -converting enzyme (ICE), 0.64 ng/ μ L and 0.128 ng/ μ L of Ebosin, EPS-7 m and EPS-7 g respectively at 37°C for 45 min.

Enzyme-linked immunosorbent assays of IL-1 β in FLS cells

FLS was seeded at 1×10^6 /mL in 24-well plates and cultivated at 37°C for 24 h. Ebosin (3.2-0.128 ng/ μ L) was added individually to each well and cultivated at 37°C for 1 h, then FLS were stimulated with LPS (5 μ g/mL per well) at 37°C for 72 h. IL-1 β in the supernatants were analyzed with ELISA kits (Applygen). The cultivated FLS cells un-stimulated with LPS were as control, while the cultivated FLS cells stimulated with LPS but not treated by Ebosin were as control 2.

Treatment of the acute inflamed mice induced by croton oil

The mice were randomly divided into three groups: acute inflammatory mice [34], Ebosin + acute inflammatory mice and EPS-7 g + acute inflammatory mice (n = 8 in each group). Ebosin and EPS-7 g (100 mg/kg) were orally administered to each mouse in the treatment groups. After 1 h, 50 μ L of 2% croton oil (in absolute ethyl alcohol) was smeared on the left auricle of each mouse in three groups for 4 h. All the mice were then sacrificed and ears were excised. The degree of ear edema was measured by weighing difference between the right and left ear.

Statistical analysis

Data were presented as the mean \pm SD from at least 3 independent experiments. The significance of differences between groups was evaluated by Student's *t*-test. *p* values less than 0.05 were considered significant.

Abbreviations

EPSs: Exopolysaccharides; FLS: Fibroblast-like synoviocytes; LAB: Lactic acid bacteria; *gtf*: Glucosyltransferase gene; ORFs: Open reading frames.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ZY carried out bioactivity experiments *in vitro* for EPS-7 g, EPS-7 m, Ebosin and analyzed the primary data. Sugar analysis of EPSs was performed by JS. YB and LB constructed the heterologous gene replacement strain *Streptomyces sp. 139 (gtf)*. RJ, LG and CY isolated EPSs. GC identified anti-inflammatory activity of EPS-7 g and Ebosin *in vivo*. YL designed and conducted the experiments. YL and RZ wrote and revised the manuscript. All the authors read and approved the final manuscript.

Acknowledgements

This research was supported by a grant from the Natural Science Foundation of China (NSFC 30530830). It has been supported by the Fundamental Research Funds for the Central Universities in China (2012 N09) and a grant from the National Key Project of New Drug Study of China (2012ZX09301002-001-023-02).

Author details

¹Key laboratory of Biotechnology of Antibiotics, Ministry of Health, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tian Tan, 100050 Beijing, China. ²Institute of Pharmacology and Toxicology, Taiping Road, 100850 Beijing, China. ³School of Biological Sciences, University of Wollongong, Wollongong, NSW 2522, Australia.

Received: 7 May 2014 Accepted: 7 July 2014

Published: 22 July 2014

References

1. Laws A, Gu Y, Marshall V: Biosynthesis, characterization and design of bacterial exopolysaccharides from lactic acid bacteria. *Biotechnol Adv* 2001, **19**:597-625.
2. Alan DW, Lan SM: Exopolysaccharides from lactic acid bacteria: perspectives and challenges. *Trends Biotechnol* 2003, **21**:269-274.
3. Cerning J: Exocellular polysaccharides produced by lactic acid bacteria. *FEMS Microbiol Rev* 1990, **7**:113-130.
4. Boels IC, Ramos A, Kleerebezem M, de Vos WM: Functional analysis of the *Lactococcus lactis* galU and gale genes and their impact on sugar nucleotide and exopolysaccharide biosynthesis. *Appl Environ Microbiol* 2001, **67**:3033-3040.
5. Jolly L, Vincent SJ, Duboc P, Neeser JR: Exploiting exopolysaccharides from lactic acid bacteria. *Antonie Van Leeuwenhoek* 2002, **82**:367-374.
6. Ruas-Madiedo P, Hugenholtz J, Zoon P: An overview of the biosynthesis and applications of heteropolysaccharides from lactic acid bacteria. *Int Dairy J* 2002, **12**:163-171.
7. Germond JE, Delley M, D'Amico N, Vincent SJ: Heterologous expression and characterization of the exopolysaccharide from *Streptococcus thermophilus* Sfi39. *Eur J Biochem* 2001, **268**:5149-5156.
8. Boels IC, van Kranenburg R, Kanning MW, Chong BF, de Vos WM, Kleerebezem M: Increased exopolysaccharide production in *Lactococcus lactis* due to increased levels of expression of the NIZO B40 *eps* gene cluster. *Appl Environ Microbiol* 2003, **69**:5029-5031.
9. Jing C, Jianbo W, Yuan L, Rong J, Baoyi L: A new IL-1 receptor inhibitor 139A: fermentation, isolation, physico-chemical properties and structure. *J Antibiot* 2003, **56**:87-90.
10. Zhang Y, Wang LF, Bai JY, Guan MJ, Jiang R, Guo LH, Wu JB, Zhang R, Cheng GF, Li Y: Anti-inflammatory effect of Ebosin on rat collagen-induced arthritis through suppression production of interferon-1 β , interferon- γ and tumor necrosis factor- α . *Eur J Inflamm* 2013, **11**:677-688.
11. Wang LY, Li ST, Li Y: Identification and characterization of a new exopolysaccharide biosynthesis gene cluster from *Streptomyces*. *FEMS Microbiol Lett* 2003, **220**:21-27.
12. Bai LP, Jiang R, Shan JJ, Guo LH, Zhang Y, Zhang R, Li Y: Purification, characterization and functional analysis of asparagine synthetase encoding by *ste10* gene in Ebosin biosynthesis of *Streptomyces sp.139*. *Enzyme Microb Technol* 2008, **42**:548-553.
13. Qi XQ, Sun QL, Bai LP, Shan JJ, Zhang Y, Zhang R, Li Y: Identification of alpha-D-glucose-1-phosphate cytidylyltransferase involved in Ebosin

- biosynthesis of *Streptomyces* sp.139. *Appl Microbiol Biotechnol* 2009, **83**:361–368.
14. Li XH, Wang L, Bai LP, Yao C, Zhang Y, Zhang R, Li Y: Cloning and characterization of a glucosyltransferase and a rhamnosyltransferase from *Streptomyces* sp.139. *J Appl Microbiol* 2010, **108**:1544–1551.
 15. Zhang Y, Zhou J, Chang M, Bai L, Shan J, Yao C, Li Y: Characterization and functional evidence for Ste27 of *Streptomyces* sp. 139 as a novel spermine/spermidine acetyltransferase. *Biochem J* 2012, **443**:727–734.
 16. Chang M, Bai LP, Shan JJ, Jiang R, Zhang Y, Guo LH, Li Y: Biochemical characteristics and function of a fucosyltransferase encoded by ste7 in Ebosin biosynthesis of *Streptomyces* sp. 139. *J Microbiol Biotechnol* 2009, **19**:1092–1097.
 17. Stinglele F, Neeser JR, Mollet B: Identification and characterization of the eps (exopolysaccharide) gene cluster from *Streptococcus thermophilus* Sfi6. *J Bacteriol* 1996, **178**:1680–1690.
 18. Boels IC, Kleerebezem M, de Vos WM: Engineering of carbon distribution between glycolysis and sugar nucleotide biosynthesis in *Lactococcus lactis*. *Appl Environ Microbiol* 2003, **69**:1129–1135.
 19. Chabot S, Yu H-L, De Léséleuc L, Cloutier D, Van Calsteren M-R, Lessard M, Roy D, Lacroix M, Oth D: Exopolysaccharides from *Lactobacillus rhamnosus* RW-9595M stimulate TNF, IL-6 and IL-12 in human and mouse cultured immunocompetent cells, and IFN- in mouse splenocytes. *Lait* 2001, **81**:683–697.
 20. Hajime N, Yutaka S, Tetsuji H: Cholesterol lowering activity of rupy fermented milk. *J Food Sci* 1992, **57**:1327–1329.
 21. Joo JH, Yun JW: Structure and molecular characterization of extracellular polysaccharides produced by *Trichoderma erinaceum* DG-312. *J Mol Biotechnol* 2005, **15**:1250–1257.
 22. Jin M, Lu Z, Huang M, Wang Y: Effects of Se - enriched polysaccharide produced by *Enterobacter cloacae* Z0206 on alloxan - induced diabetic mice. *Int J Biol Macromol* 2012, **50**:348–352.
 23. Masja NNG, Jeroen G, Michiel K: Heterologous expression of the pneumococcal serotype 14 polysaccharide in *Lactococcus lactis* requires lactococcal epsABC regulatory genes. *Appl Environ Microbiol* 2008, **74**:912–915.
 24. Knoshaug EP, Ahlgren JA, Trempey JE: Exopolysaccharide expression in *Lactococcus lactis* subsp.cremoris Ropy352: evidence for novel gene organization. *Appl Environ Microbiol* 2007, **73**:897–905.
 25. Ralf RS, Claus B, Dirk R, Norbert L, Carsten JK, Joerg RW, Dagmar P: Lipopolysaccharide activates capase-1(interleukin-1-converting enzyme) in culture monocyte and endothelial cells. *Blood* 1998, **2**:577–584.
 26. Cuzzocrea S, Mazzon E, Bevilacqua C, Costantino G, Britti D, Mazzulo G: Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. *Br J Pharmacol* 2000, **131**:1399–1407.
 27. Sambrook J, Russell DW: *Molecular cloning: a laboratory manual*. 3rd edition. Cold Spring Harbor, NY: Cold Spring Harbor Press; 2001.
 28. Kieser T, Bibb MJ, Chater KF, Hopwood DA: *Practical Streptomyces genetics*. Norwich, UK: TheJohn Innes Foundation; 2000:161–210.
 29. MacNeil DJ, Gewain KM, Ruby CL, Dezeny G, Gibbons PH, MacNeil T: Analysis of *Streptomyces avermitilis* genes required for avermectin biosynthesis utilizing a novel integration vector. *Gene* 1992, **111**:61–68.
 30. Sun QL, Wang LY, Shan JJ, Jiang R, Guo LH, Zhang Y, Zhang R, Li Y: Knockout of the gene (ste15) encoding a glycosyltransferase and its function in biosynthesis of exopolysaccharide in *Streptomyces* sp.139. *Arch Microbiol* 2007, **188**:333–340.
 31. Bitter T, Muir HM: A modified uronic acid carbazole reaction. *Anal Biochem* 1962, **4**:330–334.
 32. Zhang Y, Guo LH, Li Y: Effect of Ebosin on the inflammatory cytokines in THP-1 cells. *Acta Pharmaceutica Sinica* 2013, **48**:661–667.
 33. Koizumi F, Matsuda Y, Nakanishi S: El-1941-1 and -2, novel interleukin-1 β converting enzyme inhibitors produced by *Farrowia* sp. E-1941. *J Antibiotics* 2003, **56**:464–469.
 34. Li YT, Shen F, Bai JY, Cheng GF: Inhibition of dexamethasone, indomethacin and resveratrol on matrix methalloprotein Se-9 and the mechanism of inhibition. *Acta Pharmaceutica Sinica* 2003, **68**:501–504.

doi:10.1186/s12934-014-0103-6

Cite this article as: Zhang et al.: Characterization of an Ebosin derivative produced by heterologous gene replacement in *Streptomyces* sp. 139. *Microbial Cell Factories* 2014 **13**:103.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

